×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:RARE

Ultragenyx Pharmaceutical Insider Trading & Ownership

$62.65
+2.99 (+5.01%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$59.90
$63.30
50-Day Range
$45.80
$72.29
52-Week Range
$45.20
$104.38
Volume
16,843 shs
Average Volume
511,980 shs
Market Capitalization
$4.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.75

Ultragenyx Pharmaceutical (NASDAQ:RARE) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
6.70%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
7
Amount Of
Insider Selling
(Last 12 Months)
$3.27 M

RARE Insider Buying and Selling by Quarter

Get RARE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Ultragenyx Pharmaceutical stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Ultragenyx Pharmaceutical Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/19/2022Erik HarrisEVPSell295$54.78$16,160.1036,160  
4/16/2022Theodore Alan HuizengaCAOSell132$84.55$11,160.6016,914  
3/11/2022Thomas Richard KassbergEVPSell10,281$67.01$688,929.81  
3/7/2022Karah Herdman ParschauerEVPSell5,140$62.95$323,563.00  
3/1/2022Erik HarrisEVPSell2,713$66.62$180,740.06  
3/1/2022John Richard PinionInsiderSell4,498$66.62$299,656.76  
1/30/2022Camille L BedrosianEVPSell1,657$66.30$109,859.10  
10/14/2021Camille L BedrosianEVPSell359$81.14$29,129.26  
10/14/2021John Richard PinionInsiderSell358$81.14$29,048.12  
10/14/2021Mardi DierCFOSell3,261$81.16$264,662.76  
10/14/2021Theodore Alan HuizengaCAOSell140$81.14$11,359.60  
10/12/2021Mardi DierCFOSell3,477$82.79$287,860.83  
9/8/2021Karah Herdman ParschauerEVPSell7,336$100.65$738,368.4036,004  
9/1/2021Camille L BedrosianEVPSell2,500$100.03$250,075.00  
7/6/2021Erik HarrisEVPSell375$91.53$34,323.75  
6/21/2021Erik HarrisEVPSell572$94.96$54,317.1226,280  
6/19/2021Erik HarrisEVPSell437$94.63$41,353.3126,280  
6/10/2021Karah Herdman ParschauerEVPSell1,329$100.00$132,900.00  
5/6/2021Dennis Karl HuangEVPSell363$113.68$41,265.84  
5/6/2021Theodore Alan HuizengaCAOSell142$113.67$16,141.14  
5/3/2021Emil D. KakkisCEOSell30,000$107.80$3,234,000.00  
4/20/2021Erik HarrisEVPSell396$104.28$41,294.88  
4/15/2021Camille L BedrosianEVPSell5,000$109.09$545,450.0044,139  
3/8/2021Theodore Alan HuizengaSVPSell3,000$120.69$362,070.00  
3/1/2021Emil D KakkisCEOSell30,000$141.80$4,254,000.00596,941  
3/1/2021John Richard PinionInsiderSell6,198$138.17$856,377.6651,799  
3/1/2021Theodore Alan HuizengaSVPSell732$138.17$101,140.4417,276  
3/1/2021Thomas Richard KassbergEVPSell4,572$138.17$631,713.24106,978  
2/19/2021William AliskiDirectorSell7,500$149.01$1,117,575.0073,204  
1/30/2021Camille L. BedrosianEVPSell2,243$140.36$314,827.48  
1/7/2021Theodore Alan HuizengaSVPSell4,000$140.65$562,600.0020,436  
1/4/2021Emil D KakkisCEOSell30,000$136.90$4,107,000.00
10/30/2020Karah Herdman ParschauerEVPSell9,903$100.12$991,488.3633,871  
10/28/2020Karah Herdman ParschauerEVPSell97$100.00$9,700.0024,065  
10/14/2020Camille L. BedrosianEVPSell262$88.00$23,056.00  
10/14/2020Theodore Alan HuizengaSVPSell146$87.98$12,845.08  
10/12/2020John Richard PinionInsiderSell2,780$94.47$262,626.60  
10/8/2020Karah Herdman ParschauerEVPSell10,000$95.00$950,000.0034,293  
10/6/2020Karah Herdman ParschauerEVPSell10,000$90.00$900,000.0034,293  
9/23/2020Karah Herdman ParschauerEVPSell10,000$85.00$850,000.0034,293  
9/1/2020Emil D. KakkisCEOSell30,000$82.63$2,478,900.00  
8/17/2020Karah Herdman ParschauerEVPSell12,370$88.43$1,093,879.1036,663  
8/17/2020Shalini SharpCFOSell14,378$88.40$1,271,015.20100,747  
8/10/2020Clay B SiegallDirectorSell11,346$85.01$964,523.4618,204  
8/7/2020Clay B SiegallDirectorSell23,404$85.55$2,002,212.2018,204  
7/13/2020Emil D. KakkisCEOSell40,000$85.35$3,414,000.00  
7/8/2020Theodore Alan HuizengaSVPSell2,638$91.00$240,058.0016,582  
7/6/2020Matthew K FustDirectorSell6,181$90.00$556,290.0019,731  
7/1/2020Matthew K FustDirectorSell5,000$85.00$425,000.0018,550  
7/1/2020Theodore Alan HuizengaSVPSell2,611$81.00$211,491.0017,220  
6/3/2020Shalini SharpCFOSell10,234$74.23$759,669.82111,442  
5/26/2020Theodore Alan HuizengaSVPSell260$74.93$19,481.8018,591  
5/19/2020Shalini SharpCFOSell7,128$73.32$522,624.96122,929  
5/18/2020Karah Herdman ParschauerEVPSell2,722$74.72$203,387.84  
5/18/2020Matthew K. FustDirectorSell1,875$75.00$140,625.0055,424  
5/15/2020Theodore Alan HuizengaSVPSell2,461$71.00$174,731.0018,719  
4/22/2020Matthew K. FustDirectorSell1,875$65.00$121,875.00  
1/14/2020Theodore Alan HuizengaSVPSell1,000$61.00$61,000.00  
9/11/2019Emil D KakkisCEOBuy5,000$43.63$218,150.00472,479  
6/24/2019Karah Herdman ParschauerEVPSell1,226$61.50$75,399.00  
6/21/2019Karah Herdman ParschauerEVPSell1,489$63.01$93,821.89  
4/29/2019Karah Herdman ParschauerEVPSell468$68.30$31,964.40  
3/18/2019Shalini SharpCFOSell14,800$70.00$1,036,000.00  
12/7/2018William AliskiDirectorSell6,000$49.69$298,140.0072,610  
11/8/2018William AliskiDirectorSell6,000$55.67$334,020.0072,610  
10/8/2018William AliskiDirectorSell19,550$72.49$1,417,179.5072,610  
9/25/2018Shalini SharpCFOSell6,700$90.07$603,469.0056,828  
8/21/2018Karah Herdman ParschauerEVPSell5,000$78.53$392,650.00  
8/8/2018William AliskiDirectorSell3,750$76.66$287,475.0072,610  
6/21/2018Karah Herdman ParschauerEVPSell1,226$82.77$101,476.02  
6/15/2018Theodore Alan HuizengaVPSell955$83.70$79,933.5012,895  
6/13/2018Theodore Alan HuizengaVPSell1,338$76.97$102,985.86  
6/7/2018Shalini SharpCFOSell6,700$80.07$536,469.0060,178  
5/30/2018Matthew K FustDirectorSell6,319$72.00$454,968.008,750  
5/30/2018Shalini SharpCFOSell13,000$70.17$912,210.0070,174  
5/10/2018Karah Herdman ParschauerEVPSell1,465$60.00$87,900.00  
8/28/2017Emil D KakkisCEOBuy7,500$52.52$393,900.00430,569  
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.809,366  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.0067,887  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.0063,887  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.0065,985  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.0069,387  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.0057,387  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00480,632  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00493,244  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00513,597  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.007,111  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00526,704  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.979,216  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00552,729  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.509,608  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.5512,190  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00575,640  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.3813,231  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.002,500  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.6016,900  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00  
(Data available from 1/1/2013 forward)












Ultragenyx Pharmaceutical Insider Trading - Frequently Asked Questions

Who is on Ultragenyx Pharmaceutical's Insider Roster?

The list of insiders at Ultragenyx Pharmaceutical includes Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski. Learn more on insiders at RARE.

What percentage of Ultragenyx Pharmaceutical stock is owned by insiders?

6.70% of Ultragenyx Pharmaceutical stock is owned by insiders. Learn more on RARE's insider holdings.

Which Ultragenyx Pharmaceutical insiders have been selling company stock?

The following insiders have sold Ultragenyx Pharmaceutical stock in the last 24 months: Camille L Bedrosian ($934,513.36), Clay B Siegall ($2,966,735.66), Dennis Karl Huang ($41,265.84), Emil D Kakkis ($8,361,000.00), Erik Harris ($368,189.22), John Richard Pinion ($1,447,709.14), Karah Herdman Parschauer ($5,989,898.86), Mardi Dier ($552,523.59), Matthew K Fust ($556,290.00), Shalini Sharp ($1,271,015.20), Theodore Alan Huizenga ($1,317,374.86), Thomas Richard Kassberg ($1,320,643.05), and William Aliski ($1,117,575.00).

How much insider selling is happening at Ultragenyx Pharmaceutical?

Insiders have sold a total of 352,511 Ultragenyx Pharmaceutical shares in the last 24 months for a total of $35,709,517.26 sold.

This page (NASDAQ:RARE) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.